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Abstract: T-helper (Th) type 1/Th2 cytokines are key mediators in induction/effecter phases 
of all immune and inﬂ  ammatory responses playing role in acute/chronic renal allograft rejec-
tion. Association studies lead to identiﬁ  cation of patient risk proﬁ  les enabling individualization 
of level of immunosuppressions. We investigated the association of allograft rejection with 
interleukin-2 (IL-2), IL-4, IL-6, tumor necrosis factor-α (TNF-α) –308, transforming growth 
factor-β (TGF-β) (C-del, codon 10 and 25) gene variants in 184 renal transplant recipients and 
180 controls. These cytokine genotypes were also evaluated with cyclosporine levels (C2) at one 
month in 135 stable recipients. High producing genotypes B1B1 of IL-4 and AA of TNF-α −308 
showed signiﬁ  cant association with rejection of allograft. The dose-adjusted C2 levels were 
signiﬁ  cantly lower in patients with the high producing genotype T/T of IL-2 and heterozygous 
G/C of TGF-β codon 25 (P = 0.012 and 0.010, respectively). Haplotype frequencies were 
comparable in subjects for TGF-β codon-10 and 25. Combined inter-gene interaction showed 
high risk for rejection in recipients with high producing genotype B1B1 of IL-4 and AA of 
TNF-α and high TNF-α (AA) with low TGF-β (CC or Pro/Pro). In conclusion, association of 
IL-4 VNTR and TNF-α –308 suggested the involvement of these cytokines contributing to 
pathogenesis of allograft rejection. Recipients with TT genotype of IL-2 and GC of TGF-β 
codon 25 having low C2 levels may require higher cyclosporine dosage. Combined analysis 
of gene-gene interaction demonstrated synergistic effect of cytokines increasing risk for rejec-
tion. Thus, this information may help in pre-assessment of allograft outcome and to optimize 
cyclosporine therapy in post-transplant patients.
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Introduction
Renal transplantation is a better choice for treatment of end stage renal disease. However, 
after kidney transplantation patients need permanent immunosuppressive medication 
to prevent graft rejection and loss of graft. The mechanism of all current immunosup-
pressive drugs target T cell activation, cytokine production and clonal expansion. 
Cyclosporine and tacrolimus inhibits the phosphatase activity of calcineurin, thereby 
suppressing the production of Interleukin-2 (IL-2) and other cytokines (Myers et al 
1991). The use of immunosuppressive drugs requires a ﬁ  ne balance between adequate 
immunosuppressant to prevent rejection and excessive dosage leading to toxicity.
Genetic variations in genes encoding different T-helper (Th) type 1 and 
Th2 cytokines, chemokines and their receptors, growth factors, molecules of the 
renin–angiotensin system, enzymes of the homocysteine pathway, and proteins acting 
as substrates of immunosuppressive drugs inﬂ  uence impact on success of engraftment Biologics: Targets & Therapy 2008:2(4) 876
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and highlight the concept of genetic predisposition to 
allograft rejection (Khan et al 2006). Several studies on func-
tional variants caused by single nucleotide polymorphisms 
(SNPs) in genes encoding drug metabolizing enzymes, trans-
porters, ion channels and drug receptors have been known 
to be associated with inter-individual, interethnic variation 
in drug response and play role in inﬂ  uencing the efﬁ  cacy 
and toxicity of medications (Koo and Lee 2006). It has been 
suggested that cytokine genotyping may play a predictive 
role in identifying individuals who are at higher risk of acute 
rejection by individualizing their immunosuppression levels 
(Loucaidou et al 2005).
As polymorphisms segregate independently any one 
individual might respond with a pattern of quite different 
cytokine expression from another individual. Cytokine 
interactions are complex and it is unlikely that a single 
allelic variant results in either graft rejection or induction 
of allograft tolerance (Mas et al 2007). Heritable cytokine 
polymorphisms have been shown to account for differences 
in allograft survival. For instance, recipients of renal allograft 
whose genotypes predicted high tumor necrosis factor-α 
(TNF-α) and IL-10 production were more likely to undergo 
an acute rejection episode than individuals with genotypes 
predicting low TNF-α and IL-10 production (Sankaran et al 
1999). High IL-6 producing individuals have previously been 
shown to be at heightened risk for acute rejection (Marshall 
et al 2000). Further, Cox and colleagues (2001) observed 
an increase in IL-2 and IL-6 production associated with 
rejection events. Polymorphisms in codon 10 and codon 25 
of transforming growth factor-β (TGF-β) gene result in 
high producer phenotype and have been associated with 
chronic transplant rejection (Hutchinson et al 1999). Poole 
and colleagues (2001) reported absence of IL-4 T allele in 
both recipient and donor, ie, recipient low producer/donor 
low producer, was signiﬁ  cantly increased in rejection group. 
We thus utilized this information in evaluating the associa-
tion of IL-2, IL-4, IL-6, TNF-α, and TGF-Β cytokine gene 
polymorphisms with the risk of allograft rejection. We further 
assessed the possibility of these gene variants associations 
with cyclosporine level in stable renal transplant recipients 
from the North Indian population.
Materials and methods
Subjects
We studied one hundred eighty-four recipients of renal 
transplants from a live related donor at our tertiary 
care hospital over a period of three years (2004–2006). 
Informed consent was obtained from recipients and controls 
participating in this study. Approval of this study was 
obtained from local Ethical Committee of Sanjay Gandhi 
PGIMS, Lucknow. Transplant patients who were HbsAg 
and HCV positive were excluded from study to rule out the 
possible cause of rejection. Patients were typed for human 
leukocyte antigen (HLA) A, B and DR, DQ antigen. Controls 
(n = 180) included healthy individuals visiting the hospital 
and staff/employees with no history of hypertension, diabe-
tes, renal failure, vascular diseases, stroke/cardiomyopathy. 
Both patients and control groups had similar ethnicity.
Clinical data
The demographic and clinical details have been described 
in Table 1. Patients were followed for at least 2 years after 
transplantation. There were 34 patients (age range 19–55, 
M:F 28:6) with clinical and biopsy proven rejection episode 
(RE). All patients had single rejection episode except two, 
who experienced rejection more than once and one patient 
out of this had gone for re-transplantation. Clinical rejection 
was identiﬁ  ed as an increase in creatinine levels in absence of 
infection, obstruction or evidence of drug toxicity, associated 
with a fall to within 10% of baseline creatinine level after 
treatment. All biopsies were reviewed by a renal patholo-
gist, and the Banff 93 working classiﬁ  cation criteria were 
used in the histological classiﬁ  cation of biopsies (Racusen 
et al 1999). Fifteen patients (age range 19–53, M: F 15:0) 
experienced delayed graft functioning (DGF) who required 
dialysis within the ﬁ  rst 7–10 days of post transplantation and 
135 had stable graft functioning (SGF) (age range 17–64, 
M:F 118:17) without episode of rejection/any infection and 
obstruction except one patient who had a history of cyto-
megalovirus (CMV) infection.
Patient’s immunosuppressive therapy consisted of 
cyclosporine, azathioprine and corticosteriod. Daily doses of 
CsA were adjusted according to C-2 levels. For all patients 
the initial dosage of cyclosporine was 8 mg/kg/d to achieve 
C2 level of 1.8 μg/ml which was subsequently reduced to 1.6, 
1.4, 1.2, 1.0, and 0.8 after 1, 3, 6, and 12 months. Intravenous 
methylprednisolone was given at a standard dosage regimen 
of 500 mg of at the time of surgery, 125 mg intravenously the 
following day and then 20 mg of prednislolone daily. Oral 
prednisolone was then tapered to 10 mg daily at 3 mo trans-
plantation. There were only eight patients receiving tacrolimus 
and were not included in the study due to low number.
Cyclosporine determination
Cyclosporine (C2) values in whole blood were assayed 
with Emit (Enzyme multiplied immunologic technique) 2000 Biologics: Targets & Therapy 2008:2(4) 877
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(Dade Behring Inc, Deerﬁ  eld, IL). Peripheral blood samples 
were collected after 2 hours in morning following oral 
administration of cyclosporine post transplantation. Patient’s 
weight and daily dose of cyclosporine (in milligrams) were 
also recorded.
DNA extraction and cytokine genotyping
Genomic DNA was extracted from peripheral blood 
samples collected from transplant recipients and healthy 
volunteers by salting out method (Miller et al 1988). SNPs 
in the cytokine genes were genotyped by polymerase 
chain reaction–restriction fragment length polymorphism 
(PCR–RFLP) in IL-2, TGF-β (C-del), and TNF-α –308, 
variable number tandem repeats (VNTR) analysis in IL-4 and 
ampliﬁ  cation refractory mutatory systems (ARMS)–PCR in 
IL-6 and TGF-β (codon 10 and 25) as reported previously 
(Pociot et al 1998; Perrey et al 1999; Cox et al 2001; Tsai 
et al 2001; Gyan et al 2004; Tan et al 2005).
To improve the genotyping quality and substantiation, 
30% of samples were re-genotyped by other laboratory 
personnel and results were reproducible with no discrepancy 
recorded in genotyping. Genotyping of 10% of samples were 
conﬁ  rmed by DNA sequencing.
Data analysis
Statistical analysis was performed using the χ2 test to 
compare the genotype frequency distribution in patients 
and controls with SPSS software (version 11.5; SPSS Inc., 
Chicago, IL) using Pearson chi-square or Fisher’s exact test. 
Multinomial logistic analysis was performed to investigate 
the impact of multiple factors like age, gender and body 
weight with graft outcome. The mean concentration of 
cyclosporin and dosage and numerical values was tested by 
the Student t-test or ANOVA test. Univariate analysis with 
Bonferroni correction was performed to see the differences 
between groups SGF with RE and SGF with DGF. Odds 
ratio (OR) at 95% conﬁ  dence intervals (CI) was also deter-
mined to describe the strength of association using binary 
logistic regression model (BLRM). For nonparametric data 
of cyclosporine concentration among different genotypic 
groups Kruskal–Wallis test was employed. To examine 
whether genotype frequencies were in Hardy-Weinberg 
equilibrium, Goodness of ﬁ  t χ2 tests was used. Haplotype 
frequencies and linkage disequilibrium between each pair 
of TGF-β (codon-10 and 25) was determined by Arlequin 
(version 2.0). To analyze the haplotypes and combination 
of genotypes we did logistic regression analysis by keeping 
case-control as dependent variable and haplotype/genotypic 
combination as factors. P value   0.05 was considered 
statistically signiﬁ  cant.
Results
Association of subject characteristics
Multinomial logistic analysis was performed between RE vs 
SGF and DGF vs SGF to investigate the impact of set of pre-
dictor variables like recipient and donor age, gender and body 
weight on the outcome of allograft (ie, rejection and delayed 
Table 1 Demographic and clinical details in study population
Characteristics RE (N = 34) DGF (N = 15) SGF (N = 135) Controls (N = 180) P-value (RE and 
DGF vs SGF)
Age at time of Tx (yrs) 19–55 (34.63 ± 9.4) 19–53 (35.5 ± 10.1) 17–64 (36.10 ± 10.3) 15–67 34.96 ± 11.3 NS
*Gender (M:F) 28:6 15:0 118:17 102:78 NS
*Donor age (No)
 50 10 3 29 – NS
 50 24 12 106
CGNa (n = 154) 26 12 116 –
Othersb (n = 30) 8 3 19 –
*Body weight (kg) 36–70 (53.0 ± 8.5) 33–68 (54.3 ± 7.2) 30–80 (52.9 ± 8.8) 45–79 (55.6 ± 7.9) NS
*Cyclosporine dosage, 
1 Month (mg/d)
275–600 (367.4 ± 71.5) 273–600 (358 ± 69.3) 250–700 (386.7 ± 83.5) –N S
*Cyclosporine dosage, 
12 Month (mg/d)
100–175 (120.8 ± 20.9) 100–175 (112 ± 20.1) 50–175 (111.5 ± 23.0) –N S
*C2 conc (μg/ml), 1 mo 1.64 ± 0.12 1.61 ± 0.11 1.60 ± 0.13 – 0.032 (RE vs SGF)
Notes: aChronic glomerulonephritis; bHypertension (12), diabetes mellitus (15) and polycystic kidney disease (2) and Alport syndrome (1); *Mean ± SD; P   0.05 (Multinomial 
logistic analysis); NS, nonsigniﬁ  cant.Biologics: Targets & Therapy 2008:2(4) 878
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graft functioning). The mean concentration of cyclosporin 
dosage and C2 levels on the rejection of allograft was tested 
by the ANOVA test. Signiﬁ  cant association was seen for 
C2 levels at 1 month between RE and SGF (p = 0.032). 
However, no signiﬁ  cant difference was observed for any of 
the other factors (p   0.05) (Table 1).
Association of allograft function with combined 
effect of degree of HLA mismatches and genotypes
Evaluation was done for HLA DR, DQ mismatches (MM) in 
combination with genotypes of all the cytokine genes studied 
in RE and SGF recipients. We excluded the DGF group as 
none of the cytokine genes showed any signiﬁ  cant association 
or risk for rejection and also the number was too low for 
combined regression analysis. Recipients were divided into 
two groups: 0–2 MM and 3–4 MM and their interaction 
with genotypes was evaluated with risk of rejection using 
binary logistic regression analysis by taking SGF and RE 
as dependent variable and number of MM and genotypes as 
categorical. Binary logistic regression analysis of combined 
effect of number of DR and DQ mismatches with different 
genotypes showed no signiﬁ  cant risk for the rejection of 
allograft (Table 2).
Frequency of IL-2, IL-4, IL-6, TNF-α –308 G/A 
and TGF-β (713-8delC, codon 10 and 25) variants 
in renal transplant recipients
Genotype frequency distributions are represented in 
Table 3. The genotype frequency distributions did not 
deviate from Hardy–Weinberg equilibrium except for 
TGF-β codon 25. Frequency distribution in TGF-β 
codon 25 genotypes Arg/Arg (66.7%), Arg/Pro (23.3%) 
and Pro/Pro (10%) in our population was comparable to 
a study of McDaniel and colleagues (2003) and Skorpil 
and colleagues (2007) in African-Americans and Italian 
populations, respectively. Gendzekhadze and colleagues 
(2006) and Alakulppi and colleagues (2004) reported 0% 
frequency in mutant Pro/Pro genotype while Park and 
colleagues (2004) showed 0% in both mutant as well as 
heterozygous genotypes and 100% in wild homozygous 
(Arg/Arg), signifying that this gene may have varied 
frequencies among different populations. Duplicate 
quality control DNA samples showed  95% agreement for 
all genotyping. Further laboratory personnel were blinded 
to case–control status and to achieve  95% accuracy in 
genotyping. The genotype frequencies of total number 
of patients were compared with controls for the cytokine 
genes studied to see whether any of these cytokines were 
associated with the end stage renal disease in patients. 
Significant difference in the genotypic frequencies 
between patients and controls were observed for IL-4, 
TNF-α –308 and TGF-β codon 10 (P   0.001, Pearson 
Chi-square test).
The patients were categorized into subgroups, RE and 
DGF and were compared with SGF to study the allograft 
impact pattern and the risk for rejection. Univariate analysis was 
performed and the p-values were adjusted by Bonferroni correc-
tion (Table 4). Results revealed signiﬁ  cant differences between 
SGF and RE in IL-4 and TNF-α –308 gene (p = 0.027 and 0.012). 
The frequency of high producing genotype B1B1 was 11.8% 
in RE, 2.2% in SGF and 0.5% in controls showing  6-fold 
high risk in RE (OR, 6.815; 95%CI, 1.40–33.08; RE vs SGF; 
OR was calculated using Binary logistic regression analysis). 
Frequency of high producing genotype AA of TNF-α –308 
Table 2 Binary logistic regression analysis of combined effect 
between SGF and RE of number of mismatches with different 
genotypes predicting the risk of rejection
Variable (reference group) P-value OR, 95% CI
IL-2 (TT)-HLA DR, DQ MM 
(0–2 MM)
GG 0.284 0.313, 0.03–2.61
TG 0.475 0.705, 0.27–1.84
Il-4 (B2B2)-HLA DR, DQ MM 
(0–2 MM)
B1B1 0.999 –
B1B2 0.771 0.839, 0.25–2.73
IL-6 (CC)-HLA DR, DQ MM 
(0–2 MM)
GG 0.346 0.658, 0.27–1.57
GC 0.803 1.205, 0.27–5.23
TNF-α 308 (GG)-HLA DR, 
DQ MM (0–2 MM)
AA 0.946 0.959, 0.28–3.23
GA 0.283 0.548, 0.18–1.64
TGF-β Cod-10 (TT)-HLA DR, 
DQ MM (0–2 MM)
CC 0.745 1.304, 0.26–6.48
TC 0.165 0.522, 0.20–1.30
TGF-β Cod-25 (GG)-HLA 
DR, DQ MM (0–2 MM)
CC 0.806 0.812, 0.15–4.29
GC 0.175 0.433, 0.12–1.45
TGF-β C-del (CC/CC)-HLA 
DR, DQ MM (0–2 MM)
C/CC 0.222 0.379, 0.08–1.79
HLA DR, DQ MM (0–2 MM) 0.363 0.682, 0.29–1.55Biologics: Targets & Therapy 2008:2(4) 879
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was highest among RE as compared to SGF and controls 
(44.1%, 27.4% and 8.3%; p = 0.012, RE vs SGF). The AA 
genotype showed  7-fold higher risk for rejection (OR, 
7.905; 95%CI, 1.69–36.96; p = 0.009). TGF-β C-del showed 
a marginal signiﬁ  cance (p = 0.054) and the frequency of low 
producing genotype C/CC of TGF-β was highest among RE 
showing 2.6-fold (OR, 2.677; 95%CI, 1.06–6.74; p = 0.037). 
Further, frequency of low producing genotype pro/pro (CC) 
of TGF-β codon 10 was higher in RE (38.2%) as compared to 
SGF (20.0%) and showed 5-fold risk for rejection (OR, 5.200; 
95%CI, 1.06–25.30; p = 0.041). No signiﬁ  cant difference was 
observed between patients vs controls and RE vs SGF for IL-2, 
IL-6, and TGF-β codon 25.
Cytokine gene polymorphism and risk of delayed 
graft function
Although the number of DGF patients was quite low for 
analysis, however, analysis was done to see any risk of 
cytokine genes polymorphism associated with delayed graft 
functioning. DGF group was compared to SGF. The results 
revealed no signiﬁ  cant association for any of the cytokines 
with the risk for DGF as compared to SGF.
Effects of cytokine SNPs on cyclosporine 
dose requirement
We examined the relationship between each SNP of the 
cytokine genes and cyclosporine pharmacokinetic parameter 
C2 level μg/ml for 1 month in 135 stable renal transplant patients 
(Table 5). A Maximum variation for adjustment for dose occurs 
as during ﬁ  rst month of post-transplantation. This was a case only 
study and cyclosporine levels of the patients with their genotype 
groups were compared using Kruskal–Wallis test. Of 7 cytokine 
SNPs tested, two cytokines IL-2 and TGF-β codon 25 SNP 
were signiﬁ  cantly associated with the dose-adjusted C2 level 
(P = 0.012, and 0.010, respectively). The C2 levels were 
signiﬁ  cantly lower in patients with the high producing genotype 
T/T of IL-2 and heterozygous G/C of TGF-β codon 25.
Linkage disequilibrium and haplotype distribution
The two sites codon 10 and 25 of TGF-β have been found 
to be in linkage disequilibrium therefore we constructed 
haplotypes between these two sites to see their contribution 
to risk of disease/rejection using Arlequin software. The 
reconstructed haplotypes of contols, recipients, RE and SGF 
were compared and risk was estimated by binary logistic 
Table 3 Genotype frequencies of IL-2 –330 T/G, IL-4 VNTR, intron 3, IL-6 –174 G/C, TNF-α –308 G/A and TGF-B [713-8delC, codon 
10 T/C (Leu/Pro) and 25 G/C (Arg/Pro)] gene in transplant recipients (RE, DGF, SGF) and controls










IL-2 –330 TT (HP) 54 (30.0) 69 (37.5) 16 (47.1) 4 (26.7) 49 (36.3)
TG (Inm) 100 (55.6) 83 (45.1) 12 (35.3) 9 (60.0) 62 (45.9)
GG (LP) 26 (14.4) 32 (17.4) 6 (17.6) 2 (13.3) 24 (17.8)
IL-4 VNTR, Intron 3 B1B1 (HP) 1 (0.5) 8 (4.3) 4 (11.8) 1 (6.7) 3 (2.2)
B1B2 (Het) 95 (52.8) 60 (32.6) 12 (35.3) 8 (53.3) 40 (29.6)
B2B2 (LP) 84 (46.7) 116 (63.1) 18 (52.9) 6 (40.0) 92 (68.2)
IL-6 –174 GG (HP) 109 (68.5) 132 (71.7) 26 (76.4) 12 (80.0) 94 (69.63)
GC 53 (24) 23 (12.5) 4 (11.8) 1 (6.7) 18 (13.33)
CC (LP) 18 (7.5) 29 (15.8) 4 (11.8) 2 (13.3) 23 (17.04)
TNF-α (–308) GG 118 (65.6) 45 (24.4) 2 (5.9) 4 (26.7) 39 (28.9)
GA 47 (26.1) 84 (45.7) 17 (50.0) 8 (53.3) 59 (43.7)
AA (HP) 15 (8.3) 55 (29.9) 15 (44.1) 3 (20.0) 37 (27.4)
*TGF-B (C-del) C/CC 27 (15.0) 28 (15.2) 9 (26.5) 3 (20.0) 16 (11.9)
CC/CC (HP) 153 (85.0) 156 (84.8) 25 (73.5) 12 (80.0) 119 (88.1)
TGF-B (Codon-10) Leu/Leu (HP) 65 (36.1) 29 (15.8) 2 (5.9) 3 (20.0) 24 (17.8)
Leu/Pro 92 (51.1) 109 (59.2) 19 (55.9) 9 (60.0 81 (60.0)
Pro/Pro 23 (12.8) 46 (25.0) 13 (38.2) 3 (20.0) 30 (22.0)
TGF-B (Codon-25) Arg/Arg (HP) 120 (66.7) 116 (63.0) 22 (64.7) 10 (66.7) 84 (62.2)
Arg/Pro 42 (23.3) 36 (19.6) 6 (17.65) 2 (13.3) 28 (20.8)
Pro/Pro 18 (10.0) 32 (17.4) 6 (17.65) 3 (20.0) 23 (17.0)
Notes: P-values are for #total recipients vs Controls; IL-2: 0.136; IL-4:  0.001; IL-6:  0.001;   TNF-α:  0.001; TGF-β C-del: *0.535;   TGF-β 10:  0.001;   TGF-β 25: 0.121; #Pearson 
Chi-square; *Fischer exact test.Biologics: Targets & Therapy 2008:2(4) 880
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regression analysis for TGF-β (Table 6). The haplotype 
frequencies of TGF-β gene (codon-10 and 25) were compa-
rable in RE, SGF and controls and none of the haplotypes 
showed any risk for rejection.
Combined genotype analysis of cytokine 
gene polymorphisms
IL-4 and TNF-α showed significant association with 
rejection of allograft and cytokines are reported to show 
synergistic effect. We, therefore evaluated the combined 
inter-gene interaction of IL-4 with IL-2 and IL-6, TNF-α 
–308 and TNF-α (–308) with TGF-β (codon-10, 25 and 
C-deletion) with rejection episode taking low risk alleles 
combination of IL-4 (B2) with low IL-2 (G), IL-6 (C) and 
TNF-α –308 while high producers of TGF-β (C) as referent 
group using binary logistic regression analysis. Among dif-
ferent genotype combinations, IL-4high-IL-2low and IL-4high-
IL-2high showed signiﬁ  cantly a higher risk for RE (OR, 
3.920; 95%CI, 1.07–14.2; p = 0.038; OR, 3.360; 95%CI, 
1.03–10.9; p = 0.045, respectively) (Table 7). Signiﬁ  cant 
difference was also observed for IL-4high-TNF-α308/high and 
TNF-α308-TGF-βC-del combined genotype (p = 0.004 and 
0.005). We observed that recipients with combination of high 
IL-4 and high TNF-α; TNF-α (high producer) and TGF-β 
(low producer) are at higher risk for rejection.
Discussion
Cytokines are essential for control of immune response 
as most of the immunosuppressive drugs target cytokine 
production or their action. Inter-individual variations occur 
for sensitivity to different immunosuppressive drugs as mani-
fested by either rejection or toxicity in patients with blood 
drug concentrations within the therapeutic range.
Cytokines have the potential to inﬂ  uence various immune 
and inﬂ  ammatory responses within the graft. The difference 
in cytokine production between individuals is intensiﬁ  ed 
in presence of human leukocyte antigen (HLA) mismatch-
ing. In our study, no signiﬁ  cant association for DR and DQ 
mismatches with different cytokine genotypes for rejection 
was observed. Our observations complimented the ﬁ  ndings 
of Capei and colleagues (2004) showing that matched grafts 
were lost in same proportion as the mismatched.
A signiﬁ  cant association of high producing genotypes 
B1B1 of IL-4 and AA of TNF-α –308 with the allograft 
rejection were observed showing a higher risk for rejection. 
However, genotypic frequencies did not differ signiﬁ  cantly 
for other cytokine gene variants in our population. 
To assess the reliability we showed that recipients with 
B1B1 gene variant of IL-4 had  6-fold higher risk and AA 
of TNF-α –308 showed  7-fold higher risk. The TGF-β 
C-del showed a marginal signiﬁ  cance and the frequency of 
low producing genotype C/CC of TGF-β showed 2.6-fold 
risk. Our ﬁ  ndings showing higher frequency of rejection 
episode in recipients having high producing genotype (B1B1) 
of IL-4 corroborate the previous observation, which opined 
that Th2 cytokines promote both acute and chronic allograft 
rejection (Mhoyan et al 2003). IL-4 VNTR, intron 3 has 
not been previously reported in renal transplant patients. 
A recent study by Amirzargar and colleagues (2007) reported 
a signiﬁ  cant association of IL-4 –33 gene with renal allograft 
outcome. Strong association of TNF-α –308 polymorphism 
with rejection episode in our study are in accord with a study 
of Alakulppi and colleagues (2004) and Park and colleagues 
(2004) reporting the association of RE with AA genotype. 
On the contrary Dmitrienko and colleagues (2005) did not 
show any association of TNF-α –308 with rejection episodes. 
The TNF-α –308 G/A is a promoter polymorphism and AA 
genotype is associated with its high production. Elahi and 
colleagues (2006) suggested that increased circulating levels 
Table 4 Adjusted P-values of IL-2 −330 T/G, IL-4 VNTR, intron 3, 
IL-6 −174 G/C, TNF-α −308 G/A and TGF-B [713-8delC, codon 10 
T/C (Leu/Pro) and 25 G/C (Arg/Pro)] gene for multiple comparisons 
between SGF-RE and SGF-DGF




IL-2 −330 TT (Ref) (Ref)
TG 0.665 1.000
GG 1.000 1.000
IL-4 VNTR, Intron 3 B1B1 0.027 0.649
B1B2 0.102 0.139
B2B2 (Ref) (Ref)
IL-6 −174 GG 1.000 1.000
GC 1.000 1.000
CC (Ref) (Ref)
TNF-α (−308) GG (Ref) (Ref)
GA 0.070 1.000
AA 0.012 1.000
TGF-β (Codon-10) Leu/Leu (Ref) (Ref)
Leu/Pro 0.596 1.000
Pro/Pro 0.072 1.000
TGF-β (Codon-25) Arg/Arg (Ref) (Ref)
Arg/Pro 1.000 1.000
Pro/Pro 1.000 1.000
Notes: P = 0.054 and 0.408 for *SGF vs RE and *SGF vs DGF respectively for TGF-β 
C-del; *Fischer exact test.Biologics: Targets & Therapy 2008:2(4) 881
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of TNF-α in the rejecting kidneys trigger inducible nitric 
oxide synthase expression and damage to the microvascular 
endothelial cells, a characteristic feature of acute vascular 
rejection. Genotypic frequencies of IL-4, TNF-α –308 and 
TGF-β codon 10 differed signiﬁ  cantly between patients and 
controls showing that these variations may be linked with 
a susceptibility to suffer from ESRD, which complimented 
our earlier study in ESRD patients (Manchanda et al 2006; 
Mittal and Manchanda 2007a, 2007b).
One of the strategies used currently to overcome rejection 
episode was to correlate affected cytokine gene polymorphism 
with immunosuppressant like cyclosporine levels, a calcineurin 
inhibitor used for preventing allograft rejection. Its pharma-
cokinetic characteristics vary greatly among individuals, 
and daily doses are adjusted to whole-blood cyclosporine 
concentration.
The role of cytokines variation in cyclosporine 
pharmacogenetics can be well explained by a study by 
Hartel and colleagues (2004) who opined the ability of 
immunosuppressive drugs to remove the negative regulatory 
signals for IL-2-like IL-10, due to inter-individual variation. 
Out of 7 cytokine SNPs tested, two cytokines IL-2 and 
Table 5 Inﬂ  uence of cytokines genotypes on cyclosporine trough blood levels and dose requirements at one month in stable renal 
allograft patients
Genotype Allelic status (n) 
dose requirement
(C2 level μg/ml) p-value†
IL-2 −330 T/T (49) 1.56 ± 0.13
T/G T/G (62) 1.64 ± 0.12 0.012
G/G (24) 1.63 ± 0.15
IL-4 B1/B1 (3) 1.60 ± 0.14
VNTR, Intron3 B1/B2 (40) 1.61 ± 0.12 0.621
B2/B2 (92) 1.64 ± 0.12
Il-6 −174 G/G (94) 1.56 ± 0.14
G/C G/C (18) 1.60 ± 0.13 0.363
C/C (23) 1.62 ± 0.13
TNF-α −308 G/G (39) 1.59 ± 0.09 0.209
G/A G/A (59) 1.60 ± 0.16
A/A (37) 1.63 ± 0.12
TGF-β Codon10 T/T (24) 1.57 ± 0.17
T/C T/C (81) 1.61 ± 0.13 0.563
C/C (30) 1.63 ± 0.12
TGF-β Codon 25 G/G (84) 1.62 ± 0.15
G/C G/C (28) 1.56 ± 0.12 0.010
C/C (23) 1.62 ± 0.07
TGF-β C-del CC/CC (119) 1.60 ± 0.14 0.544
C-deletion C/CC (16) 1.62 ± 0.09
Notes: Values are given as arithmetic mean ± SD; *P   0.05 (†Kruskal–Wallis test).









P, OR; 95% CI 
(*Recipients vs 
Controls)
P, OR; 95% CI 
(*RE vs SGF)
Leu-Arg 88 (48.9) 68 (37.0) 16 (47.1) 49 (36.3) 1.0 (Ref) 1.0 (Ref)
Pro-Arg 54 (30.0) 66 (35.9) 10 (29.4) 49 (36.3) 0.061, 1.582; (0.98–2.55) 0.297, 0.625; (0.25–1.51)
Pro-Pro 15 (8.3) 19 (10.3) 1 (2.9) 14 (10.4) 0.195, 1.639; (0.77–3.46) 0.157, 0.219; (0–0)
Leu-Pro 23 (12.8) 31 (16.8) 7 (20.6) 23 (17.0) 0.081, 1.744; (0.93–3.26) 0.892, 0.932; (0.33–2.57)
Note: *Binary Logistic regression analysis.Biologics: Targets & Therapy 2008:2(4) 882
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TGF-β codon 25 SNP were signiﬁ  cantly associated with 
dose-adjusted C2 level showing that C2 level was lower 
or possibly better absorption of cyclosporine in patients 
with TT genotype of IL-2 and heterozygous GC of TGF-β. 
This is perhaps a ﬁ  rst report from north Indian population 
showing a signiﬁ  cant association of cytokine gene variants 
with cyclosporine dose requirement.
Cytokines illustrate synergistic effect if the combined 
effect of two cytokines on cellular activity is greater than the 
additive effects of individual cytokine. A combined analysis 
of the effect of IL-4 in combination with IL-2 showed 
signiﬁ  cant risk with both low and high IL-2 genotypes. 
Another combination of high IL-4 with high TNF-α demon-
strated a signiﬁ  cant higher risk for rejection. This observation 
suggested that IL-4 cytokine could have synergistic effect 
with TNF-A reﬂ  ecting gene-gene interaction. The other 
combination of TNF-α (–308) with TGF-B projecting 
recipients with TNF-α308/high-TGF-βC-del/low associated with 
higher risk of rejection. Our observations suggested that high 
producing genotypes of proinﬂ  ammatory cytokine TNF-α 
and low producing genotypes of TGF-β (anti-inﬂ  ammatory) 
may have a major impact on the immune response responsible 
for allograft acceptance/rejection (Park et al 2004).
IL-2 did not show any signiﬁ  cant association with the 
rejection in our population, which is in agreement to the study 
of Poli and colleagues (2001) and Pawlik and colleagues 
(2005a) showing no association of IL-2 –330 with acute 
rejection after kidney transplantation. The reason behind 
no association of IL-2 could be that patients are given high 
therapeutic doses of CsA during the early period of transplan-
tation. It is plausible that a standard high dose of CsA may be 
adequate for the complete blockage of IL-2 production in indi-
viduals that carry high producer IL-2 genotype thus leading 
to better graft survival. It is known that under conditions of 
Table 7 Allograft rejection risk for combined effect of cytokine gene polymorphisms between SGF and RE
Combined genotype RE (n = 34); (%) SGF (n = 135); (%)
*OR at 95% CI; p-value
IL-4high-IL-2low 7 (20.6) 15 (11.1) 3.920 (1.07–14.2); 0.038
IL-4high-IL-2high 10 (29.4) 25 (18.5) 3.360 (1.03–10.9); 0.045
IL-4low-IL-2high 12 (35.3) 53 (39.3) 1.902 (0.62–5.8); 0.260
IL-4low-IL-2low 5 (14.7) 42 (31.1) 1.00 (Reference)
IL-4high-IL-6low 3 (8.8) 11 (8.1) 1.052 (0.22–4.82); 0.948
IL-4high-IL-6high 13 (38.2) 31 (23.0) 1.618 (0.56–4.6); 0.371
IL-4low-IL-6high 11 (32.3) 66 (48.9) 0.643 (0.22–1.83); 0.409
IL-4low-IL-6low 7 (20.6) 27 (20.0) 1.00 (Reference)
IL-4high-TNF-α308/low 3 (8.8) 6 (4.4) 2.149 (0.43–10.52); 0.345
IL-4high-TNF-α308/high 18 (53.0) 32 (23.7) 9.600 (2.05–44.93); 0.004
IL-4low-TNF-α308/high 10 (29.4) 65 (48.2) 8.000 (1.09–58.54); 0.041
IL-4low-TNF-α308/low 3 (8.8) 32 (23.7) 1.00 (Reference)
TNF-α308/low-TGF-β10/high 1 (2.9) 10 (7.4) 1.00 (Reference)
TNF-α308/high-TGF-β10/low 29 (85.3) 82 (60.7) 3.537 (0.43–28.84); 0.238
TNF-α308/high-TGF-β10/high 2 (5.9) 14 (10.4) 1.429 (0.11–18.00); 0.783
TNF-α308/low-TGF-β10/low 2 (5.9) 29 (21.5) 0.690 (–); 0.771
TNF-α308/low-TGF-β25/high 1 (2.9) 27 (20.0) 1.00 (Reference)
TNF-α308/high-TGF-β25/low 10 (29.4) 39 (28.9) 6.923 (0.83–57.29); 0.073
TNF-α308/high-TGF-β25/high 21 (61.8) 57 (42.2) 0.029, 9.947 (1.27–77.86)
TNF-α308/low-TGF-β25/low 2 (5.9) 12 (8.9) 0.237, 4.500 (0.37–54.54)
TNF-α308/low-TGF-βC-del/high 2 (5.9) 35 (25.9) 1.00 (Reference)
TNF-α308/high-TGF-βC-del/low 9 (26.5) 12 (8.9) 0.002, 13.125 (2.47–69.48)
TNF-α308/high-TGF-βC-del/high 23 (67.6) 84 (62.2) 0.040, 4.792 (1.07–21.42)
TNF-α308/low-TGF-βC-del/low 0 (0.0) 4 (3.0) –
Note: *Binary logistic regression analysis.Biologics: Targets & Therapy 2008:2(4) 883
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allo-stimulation and immunosuppression, the inﬂ  uence of the 
T/T and T/G genotypes on IL-2 production could be different 
from that observed in vitro (Morgun et al 2003).
IL-6 polymorphism did not reﬂ  ect any association in 
our population. Our ﬁ  ndings are in agreement with Poli and 
colleagues (2001) and Lacha and colleagues (2005) showing 
no association of IL-6 with rejection. On the contrary Pawlik 
and colleagues (2005b) demonstrated IL-6 CC genotype to 
be associated with an increased risk of rejection. Contradic-
tion in results perhaps could be best resolved by functional 
studies that may be required to provide new insights into 
the role of IL-6.
TGF-β is a pleiotropic cytokine with unique and potent 
anti-inﬂ  ammatory and there are several reports showing 
the protective roles of TGF-β (Ma et al 2004; Wang et al 
2005). Analysis of TGF-β C-del, codon-10 and 25 revealed 
that low producing genotype C/CC of C-del and ‘Pro-Pro’ 
of codon-10 was signiﬁ  cantly associated with higher risk 
for rejection which complimented the study by Park and 
colleagues (2004).
Delayed graft function is linked to several long-term 
risks for acute rejection subsequently leading to allograft 
dysfunction and graft loss. A number of clinical factors may 
be linked with DGF. We did not detect signiﬁ  cant difference 
in cytokine gene variants in patients of SGF and DGF, which 
could be related to the small number of patients studied. Our 
ﬁ  ndings corroborate with the studies of Alakulppi and col-
leagues (2004) and Pawlik and colleagues (2005b) who in 
their study too, reported no association of different cytokines 
gene studied with delayed graft functioning.
Due to an high degree of LD observed between SNPs of 
TGF-β codon 10 and 25, disease variants may be revealed 
through evaluation of underlying haplotypes. Hence we con-
structed haplotypes for TGF-β polymorphism in our study. 
TGF-β gene (codon-10 and 25) haplotype frequencies were 
comparable in RE, SGF and controls. Haplotypic frequency 
of TGF-B in our population matched with the Caucasians 
(Coll et al 2004).
The sample size, though low, may be a limitation due 
to single centre, nevertheless, the results obtained from 
this present study constituted a preliminary step and initial 
understanding of the role of cytokine gene polymophism in 
renal transplant. Hence, further analyses in large multicenter 
allograft series are warranted.
Conclusion
Strong associations of high producing genotypes B1B1 of 
IL-4 and AA of TNF-α –308 while low producing genotype 
Pro/Pro of TGF-β codon-10 in our population substantiate 
that both Th1 and Th2 derived cytokines could be an impor-
tant risk factor for kidney transplant rejection. High producing 
genotype TT of IL-2 and heterozygous GC of TGF-β codon 
25 polymorphism were highly associated with cyclosporine 
dose requirements in stable renal transplant patients sug-
gesting that recipients may require higher dose with these 
genotypes. Combined genotype analysis of gene-gene inter-
action demonstrated synergistic effect of TNF-α with IL-4 
and TGF-β increasing the risk for rejection. Our study further 
suggests that pre-transplantation assessment of this variability 
could be a powerful tool for better choice of immunosuppres-
sive agents for optimization of individual immunosuppressive 
therapy. Given the importance of rapidly achieving target 
blood concentrations after transplantation, further prospective 
studies should consider the immediate post-graft period and 
assess the inﬂ  uence of speciﬁ  c polymorphism.
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